US 12144813
PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 12144813 (PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer) held by Cardiff Oncology, Inc. expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Cardiff Oncology, Inc.
- Grant date
- Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K2300/00, A61K31/437